ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colonic Cancer
Colorectal Cancer
Rectal Cancer
Non-Small-Cell Lung Carcinoma
Pancreatic Cancer
Cancer
Neoplasm Metastasis

Colon Cancer trials near Baltimore, MD, USA:

Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer

and pembrolizumab, before surgery can treat a common type of colon cancer called microsatellite stable (MSS) colon cancer...

Begins enrollment this month
Proficient Mismatch Repair (pMMR) Colon Cancer
Microsatellite Stable (MSS) Colon Cancer
Drug: Porustobart
Drug: Pembrolizumab

Phase 2

Solstice Oncology, Inc.

Baltimore, Maryland, United States and 29 other locations

(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...

Enrolling
Colonic Neoplasms
Neoplasms, Colon
Drug: CAPEOX
Biological: Dostarlimab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Bethesda, Maryland, United States and 262 other locations

and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to:* Evaluate the efficacy of the...

Enrolling
Colorectal Cancer (CRC)
Colon Cancer
Drug: fruquintinib
Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)

Phase 2

SCRI Development Innovations

Columbia, Maryland, United States and 13 other locations

activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer...

Enrolling
Colorectal Cancer (CRC)
Colon Cancer
Biological: CBI-1214

Phase 1

Cartography Biosciences

Fairfax, Virginia, United States of America and 9 other locations

or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcino...

Enrolling
Pancreatic Cancer
Colorectal Cancer
Drug: KRAS Vaccine with Poly-ICLC adjuvant
Drug: Balstilimab

Phase 1

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitr...

Active, not recruiting
Glioma
Chondrosarcoma
Drug: LY3410738
Drug: Gemcitabine

Phase 1

Lilly
Lilly

Baltimore, Maryland, United States and 32 other locations

to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer...

Active, not recruiting
Colon Cancer
Medullary Thyroid Cancer
Drug: LOXO-292

Phase 1, Phase 2

Lilly
Lilly

Baltimore, Maryland, United States and 85 other locations

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant sol...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: RMC-6236
Drug: RMC-9805

Phase 1

Revolution Medicines
Revolution Medicines

Baltimore, Maryland, United States and 16 other locations

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012,...

Enrolling
Advanced Cancer
Colon Cancer
Drug: PHN-012

Phase 1

Pheon Therapeutics

Washington D.C., District of Columbia, United States and 25 other locations

and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to evaluate sa...

Active, not recruiting
Pancreatic Cancer
Colorectal Cancer
Drug: Nivolumab
Drug: Ipilimumab

Phase 1

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems